GlassScriptPhysician profile
Ahsan Basha
NPI 1043283849
$2,419.39
in general payments reported to CMS, 2019-2025
36 companies · $1,347 in 2025
The $1,347 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.55 · 2020: $74.99 · 2021: $11.70 · 2022: $199 · 2023: $324 · 2024: $415 · 2025: $1,347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,053 · Education: $32.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,053.23 |
| Education | $32.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $232.87 | 2023-2025 | |
| Gilead Sciences, INC. | $185.83 | 2022-2025 | Trodelvy |
| Pfizer INC. | $179.64 | 2023-2025 | |
| Janssen Biotech, INC. | $171.58 | 2020-2025 | Darzalex, Talvey, Tecvayli |
| Abbvie INC. | $164.90 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $144.10 | 2023-2025 | Enhertu, Calquence, Lynparza |
| Celgene Corporation | $130.62 | 2023-2025 | Reblozyl, Pomalyst |
| Merck Sharp & Dohme LLC | $117.92 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Jazz Pharmaceuticals INC. | $106.12 | 2024-2025 | |
| Eisai INC. | $80.99 | 2023-2025 | |
| Lilly USA, LLC | $78.35 | 2025 | Verzenio, Jaypirca |
| Array Biopharma INC | $77.78 | 2025 | Mektovi, Braftovi, Tukysa |
| Tolmar Pharmaceuticals, INC. | $76.50 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $73.73 | 2024-2025 | Opdivo |
| Amgen INC. | $54.91 | 2019-2025 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahsan Basha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.